Cargando…
Better Progression-Free Survival in Elderly Patients with Stage IV Lung Adenocarcinoma Harboring Uncommon Epidermal Growth Factor Receptor Mutations Treated with the First-line Tyrosine Kinase Inhibitors
Patients with lung adenocarcinoma harboring common epidermal growth factor receptor (EGFR) mutations usually have a good response rate (RR) and longer progression-free survival (PFS) to EGFR tyrosine kinase inhibitors (TKIs). However, the treatment efficacy to uncommon EGFR mutations remains controv...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6266446/ https://www.ncbi.nlm.nih.gov/pubmed/30428509 http://dx.doi.org/10.3390/cancers10110434 |
_version_ | 1783375841016676352 |
---|---|
author | Tsai, Ming-Ju Hung, Jen-Yu Lee, Mei-Hsuan Kuo, Chia-Yu Tsai, Yu-Chen Tsai, Ying-Ming Liu, Ta-Chih Yang, Chih-Jen Huang, Ming-Shyan Chong, Inn-Wen |
author_facet | Tsai, Ming-Ju Hung, Jen-Yu Lee, Mei-Hsuan Kuo, Chia-Yu Tsai, Yu-Chen Tsai, Ying-Ming Liu, Ta-Chih Yang, Chih-Jen Huang, Ming-Shyan Chong, Inn-Wen |
author_sort | Tsai, Ming-Ju |
collection | PubMed |
description | Patients with lung adenocarcinoma harboring common epidermal growth factor receptor (EGFR) mutations usually have a good response rate (RR) and longer progression-free survival (PFS) to EGFR tyrosine kinase inhibitors (TKIs). However, the treatment efficacy to uncommon EGFR mutations remains controversial. We, therefore, performed a retrospective study, screening 2958 patients. A total of 67 patients with lung adenocarcinoma harboring uncommon EGFR mutations were enrolled and 57 patients with stage IV diseases receiving a first-line EGFR TKI were included for further analyses. The patients were classified into 27 (47%) “a single sensitizing uncommon mutation”, 7 (12%) “multiple sensitizing mutations”, 5 (9%) “a sensitizing mutation and a resistant uncommon mutation”, and 18 (32%) “other resistant uncommon mutations”. No significant difference was noted in PFS or overall survival (OS) between groups. Patients receiving different first-line EGFR TKIs had similar PFS and OS. The elder patients had a significantly poorer performance status than the younger patients but a significantly longer PFS than the younger patients (median PFS: 10.5 vs. 5.5 months, p = 0.0320). In conclusion, this is the first study to identify that elderly patients with stage IV lung adenocarcinoma harboring uncommon EGFR mutation might have a longer PFS. Large-scale prospective studies are mandatory to prove our findings. |
format | Online Article Text |
id | pubmed-6266446 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-62664462018-12-03 Better Progression-Free Survival in Elderly Patients with Stage IV Lung Adenocarcinoma Harboring Uncommon Epidermal Growth Factor Receptor Mutations Treated with the First-line Tyrosine Kinase Inhibitors Tsai, Ming-Ju Hung, Jen-Yu Lee, Mei-Hsuan Kuo, Chia-Yu Tsai, Yu-Chen Tsai, Ying-Ming Liu, Ta-Chih Yang, Chih-Jen Huang, Ming-Shyan Chong, Inn-Wen Cancers (Basel) Article Patients with lung adenocarcinoma harboring common epidermal growth factor receptor (EGFR) mutations usually have a good response rate (RR) and longer progression-free survival (PFS) to EGFR tyrosine kinase inhibitors (TKIs). However, the treatment efficacy to uncommon EGFR mutations remains controversial. We, therefore, performed a retrospective study, screening 2958 patients. A total of 67 patients with lung adenocarcinoma harboring uncommon EGFR mutations were enrolled and 57 patients with stage IV diseases receiving a first-line EGFR TKI were included for further analyses. The patients were classified into 27 (47%) “a single sensitizing uncommon mutation”, 7 (12%) “multiple sensitizing mutations”, 5 (9%) “a sensitizing mutation and a resistant uncommon mutation”, and 18 (32%) “other resistant uncommon mutations”. No significant difference was noted in PFS or overall survival (OS) between groups. Patients receiving different first-line EGFR TKIs had similar PFS and OS. The elder patients had a significantly poorer performance status than the younger patients but a significantly longer PFS than the younger patients (median PFS: 10.5 vs. 5.5 months, p = 0.0320). In conclusion, this is the first study to identify that elderly patients with stage IV lung adenocarcinoma harboring uncommon EGFR mutation might have a longer PFS. Large-scale prospective studies are mandatory to prove our findings. MDPI 2018-11-13 /pmc/articles/PMC6266446/ /pubmed/30428509 http://dx.doi.org/10.3390/cancers10110434 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Tsai, Ming-Ju Hung, Jen-Yu Lee, Mei-Hsuan Kuo, Chia-Yu Tsai, Yu-Chen Tsai, Ying-Ming Liu, Ta-Chih Yang, Chih-Jen Huang, Ming-Shyan Chong, Inn-Wen Better Progression-Free Survival in Elderly Patients with Stage IV Lung Adenocarcinoma Harboring Uncommon Epidermal Growth Factor Receptor Mutations Treated with the First-line Tyrosine Kinase Inhibitors |
title | Better Progression-Free Survival in Elderly Patients with Stage IV Lung Adenocarcinoma Harboring Uncommon Epidermal Growth Factor Receptor Mutations Treated with the First-line Tyrosine Kinase Inhibitors |
title_full | Better Progression-Free Survival in Elderly Patients with Stage IV Lung Adenocarcinoma Harboring Uncommon Epidermal Growth Factor Receptor Mutations Treated with the First-line Tyrosine Kinase Inhibitors |
title_fullStr | Better Progression-Free Survival in Elderly Patients with Stage IV Lung Adenocarcinoma Harboring Uncommon Epidermal Growth Factor Receptor Mutations Treated with the First-line Tyrosine Kinase Inhibitors |
title_full_unstemmed | Better Progression-Free Survival in Elderly Patients with Stage IV Lung Adenocarcinoma Harboring Uncommon Epidermal Growth Factor Receptor Mutations Treated with the First-line Tyrosine Kinase Inhibitors |
title_short | Better Progression-Free Survival in Elderly Patients with Stage IV Lung Adenocarcinoma Harboring Uncommon Epidermal Growth Factor Receptor Mutations Treated with the First-line Tyrosine Kinase Inhibitors |
title_sort | better progression-free survival in elderly patients with stage iv lung adenocarcinoma harboring uncommon epidermal growth factor receptor mutations treated with the first-line tyrosine kinase inhibitors |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6266446/ https://www.ncbi.nlm.nih.gov/pubmed/30428509 http://dx.doi.org/10.3390/cancers10110434 |
work_keys_str_mv | AT tsaimingju betterprogressionfreesurvivalinelderlypatientswithstageivlungadenocarcinomaharboringuncommonepidermalgrowthfactorreceptormutationstreatedwiththefirstlinetyrosinekinaseinhibitors AT hungjenyu betterprogressionfreesurvivalinelderlypatientswithstageivlungadenocarcinomaharboringuncommonepidermalgrowthfactorreceptormutationstreatedwiththefirstlinetyrosinekinaseinhibitors AT leemeihsuan betterprogressionfreesurvivalinelderlypatientswithstageivlungadenocarcinomaharboringuncommonepidermalgrowthfactorreceptormutationstreatedwiththefirstlinetyrosinekinaseinhibitors AT kuochiayu betterprogressionfreesurvivalinelderlypatientswithstageivlungadenocarcinomaharboringuncommonepidermalgrowthfactorreceptormutationstreatedwiththefirstlinetyrosinekinaseinhibitors AT tsaiyuchen betterprogressionfreesurvivalinelderlypatientswithstageivlungadenocarcinomaharboringuncommonepidermalgrowthfactorreceptormutationstreatedwiththefirstlinetyrosinekinaseinhibitors AT tsaiyingming betterprogressionfreesurvivalinelderlypatientswithstageivlungadenocarcinomaharboringuncommonepidermalgrowthfactorreceptormutationstreatedwiththefirstlinetyrosinekinaseinhibitors AT liutachih betterprogressionfreesurvivalinelderlypatientswithstageivlungadenocarcinomaharboringuncommonepidermalgrowthfactorreceptormutationstreatedwiththefirstlinetyrosinekinaseinhibitors AT yangchihjen betterprogressionfreesurvivalinelderlypatientswithstageivlungadenocarcinomaharboringuncommonepidermalgrowthfactorreceptormutationstreatedwiththefirstlinetyrosinekinaseinhibitors AT huangmingshyan betterprogressionfreesurvivalinelderlypatientswithstageivlungadenocarcinomaharboringuncommonepidermalgrowthfactorreceptormutationstreatedwiththefirstlinetyrosinekinaseinhibitors AT chonginnwen betterprogressionfreesurvivalinelderlypatientswithstageivlungadenocarcinomaharboringuncommonepidermalgrowthfactorreceptormutationstreatedwiththefirstlinetyrosinekinaseinhibitors |